{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:43:27Z","timestamp":1790142207750,"version":"4.0.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ftd.0b013e3182603f62","type":"journal-article","created":{"date-parts":[[2012,7,7]],"date-time":"2012-07-07T11:47:17Z","timestamp":1341661637000},"page":"415-421","source":"Crossref","is-referenced-by-count":25,"title":["Plasma Concentrations of Quetiapine, N-Desalkylquetiapine, O-Desalkylquetiapine, 7-Hydroxyquetiapine, and Quetiapine Sulfoxide in Relation to Quetiapine Dose, Formulation, and Other Factors"],"prefix":"10.1097","volume":"34","author":[{"given":"Danielle S.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S146114571000101X","article-title":". Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.","volume":"14","author":"Wang","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":". Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","article-title":". Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.","volume":"72","author":"Sparshatt","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/NDT.S4903","article-title":"Role of extended release quetiapine in the management of bipolar disorders.","volume":"6","author":"Al Jurdi","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1755-5949.2010.00217.x","article-title":". The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.","volume":"17","author":"DellOsso","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"R6-9-20210129","first-page":"501","article-title":". Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.","volume":"6","author":"Gedge","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":". N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1a agonist, as a putative mediator of quetiapines antidepressant activity.","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","article-title":"Second-generation antipsychotics in major depressive disorder: update and clinical perspective.","volume":"24","author":"Chen","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":". Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.","volume":"13","author":"Bandelow","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2010.08.032","article-title":". A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder.","volume":"127","author":"Bauer","year":"2010","journal-title":"J Affect Disord"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":". Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/da.20740","article-title":". Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.","volume":"27","author":"Liebowitz","year":"2010","journal-title":"Depress Anxiety"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0269881108100774","article-title":"The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice.","volume":"24","author":"Shajahan","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/JCP.0b013e3181f1d0f2","article-title":". A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms.","volume":"30","author":"Soares","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2008.12.016","article-title":"Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study.","volume":"117","author":"Anderson","year":"2009","journal-title":"J Affect Disord"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1345\/aph.1M193","article-title":"Safety and efficacy of quetiapine in bipolar depression.","volume":"43","author":"Bogart","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hup.970","article-title":". Quetiapine augmentation in depressed patients with partial response to antidepressants.","volume":"23","author":"Olver","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1517\/14656566.8.14.2207","article-title":". Two weeks quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels.","volume":"8","author":"Mauri","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-5618.2007.00479.x","article-title":". Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.","volume":"9","author":"Vieta","year":"2007","journal-title":"Bipolar Disord"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":". Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","article-title":". Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.","volume":"33","author":"Figueroa","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":". Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.","volume":"18","author":"Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R24-9-20210129","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.","volume":"63","author":"Nemeroff","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patientsthe influence of comedication.","volume":"26","author":"Hasselstrom","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review.","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":". Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.","volume":"37","author":"Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0269881110389208","article-title":". Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.","volume":"25","author":"Nikisch","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2011.07.001","article-title":". N-desalkylquetiapine activates ERK12 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant.","volume":"62","author":"Di Benedetto","year":"2012","journal-title":"Neuropharmacology"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":". Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations.","volume":"21","author":"Aichhorn","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jpsychires.2010.02.004","article-title":". Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.","volume":"44","author":"Nikisch","year":"2010","journal-title":"J Psychiatr Res"},{"key":"R35-9-20210129","first-page":"390","article-title":". Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.","volume":"25","author":"Li","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","article-title":". A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).","volume":"71","author":"McElroy","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R37-9-20210129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","article-title":". A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).","volume":"71","author":"Young","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":". Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R39-9-20210129","first-page":"CD008120","article-title":". Second-generation antipsychotics for anxiety disorders.","volume":"8","author":"Depping","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R40-9-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YIC.0b013e3283457d73","article-title":". Augmentative quetiapine in partialnonresponders with generalized anxiety disorder: a randomized, placebo-controlled study.","volume":"26","author":"Altamura","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e3283430a0e","article-title":". Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials.","volume":"26","author":"Zhornitsky","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":". Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.","volume":"121","author":"Suppes","year":"2010","journal-title":"J Affect Disord"},{"key":"R43-9-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00702-005-0331-3","article-title":". Region specific distribution of levomepromazine in the human brain.","volume":"113","author":"Kornhuber","year":"2006","journal-title":"J Neural Transm"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182603f62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:50Z","timestamp":1620952790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201208000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182603f62","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}